Allison Bratzel

Anupam Rama

Evan Seigerman

Jiale Song

Jonathan Chang

Peter Lawson

- Replimune Group, Inc. (REPL) stock **plummeted by 77%** on **July 22, 2025**, after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for its leading cancer drug, RP1, effectively halting its approval process.  **[1737953_b9c7f0653a8741e4af881ac599666367_0]** 
- A securities class action lawsuit, _Jboor v. Replimune Group, Inc., et al._, has been filed, alleging Replimune **misled investors** by overstating RP1's trial data and failing to disclose critical regulatory risks.  **[1737953_b9c7f0653a8741e4af881ac599666367_0]** 
- The lawsuit covers investors who purchased Replimune securities between **November 22, 2024, and July 21, 2025**, with a Lead Plaintiff Deadline of **September 22, 2025**.  **[1737953_b9c7f0653a8741e4af881ac599666367_0]** 
- The FDA's rejection of RP1 was based on issues with the IGNYTE trial's methodology, specifically citing **patient heterogeneity** and flaws in the design of the planned confirmatory trial.  **[1737953_b9c7f0653a8741e4af881ac599666367_0]**

Replimune Group (REPL)